Purchase this article with an account.
M. A. Kass, M. O. Gordon, J. A. Huecker, J. Keltner, R. Parrish, C. A. Johnson, Ocular Hypertension Study Group (OHTS); Incidence of Glaucomatous Visual Field Loss Subsequent to Initial Glaucomatous Optic Disc Deterioration in the Ocular Hypertension Treatment Study (OHTS). Invest. Ophthalmol. Vis. Sci. 2010;51(13):2047.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To determine the incidence of glaucomatous visual field loss subsequent to a primary glaucomatous optic disc endpoint in the Ocular Hypertension Treatment Study (OHTS)
Humphrey visual fields were done every 6 months and stereoscopic optic disc photographs were taken every 12 months. These were reviewed by masked graders in reading centers. An incident case of POAG required 3 consecutive abnormal visual fields or 2 consecutive stereophotographs showing progression that was then attributed to glaucoma by a masked Endpoint Committee. After development of POAG, participants in the observation group initiated ocular hypotensive treatment and participants in the medication group continued treatment. From 2/94 to approximately 6/02, 84 participants developed glaucomatous optic disc deterioration, 59 developed glaucomatous visual field abnormalities and 12 developed both glaucomatous visual field and optic disc deterioration in the same eye. This report includes participants who developed either visual field or optic disc POAG endpoint but not both in the same eye. We report the incidence of POAG visual field abnormality subsequent to initial POAG optic disc deterioration in the same eye and conversely, the incidence of POAG optic disc deterioration subsequent to initial POAG visual field abnormalities in the same eye.
Median follow-up after the initial diagnosis of POAG was 7.9 years. The Incidence of POAG endpoints subsequent to the initial optic disc or visual field POAG endpoint is reported in the table below.
Despite medical treatment, a substantial proportion of eyes in which glaucomatous damage is initially detected by either disc progression or visual field abnormality subsequently develop reproducible damage in the other modality.
This PDF is available to Subscribers Only